Tag: DMD

New warning on Sarepta’s Elevidys gene therapy for DMD

Adam Feuerstein, a senior writer and biotech columnist, delved into the recent warnings and restrictions placed on Sarepta

Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data

Dyne Therapeutics Inc. (NASDAQ:DYN) stands out as one of the top stocks priced under $20. On September 29,